Advertisement

Topics

The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C Company Profile

14:24 EST 20th November 2017 | BioPortfolio


News Articles [1170 Associated News Articles listed on BioPortfolio]

Eliminate hepatitis: WHO

New WHO data from 28 countries - representing approximately 70% of the global hepatitis burden - indicate that efforts to eliminate hepatitis are gaining momentum. Published to coincide with World H...

World Hepatitis Day sets the stage for the elimination of viral hepatitis

(World Hepatitis Alliance) Today, World Hepatitis Day, marks the first time that the global health community has come together to officially begin moving towards the elimination of viral hepatitis by ...

Center for Domestic Preparedness welcomes LSCC students to incident response course

The Center for Domestic Preparedness (CDP) in Anniston, Alabama, hosted students from Lawson State Community College (LSCC) for the first time on March 23. Read more..

China Food and Drug Administration Approves Gilead's Sovaldi (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection

- Sovaldi-based Regimens Demonstrated High Rates of Sustained Virologic Response or Cure for Chinese Hepatitis C Infected Patients - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the C...

World Hepatitis Day – gearing towards eliminating viral hepatitis by 2030

July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown ...

FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention

Dynavax Technologies announced that the FDA has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adu...

Nine in 10 people unaware they have hepatitis

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with an emphasis that much work is left to be done to combat the viral infection. The org...

Sustained Response to Direct-acting HCV Antivirals Tied to Lower HCC Risk

A sustained virologic response to direct-acting antiviral treatment of hepatitis C (HCV) is associated with a “considerable” reduction in the risk of hepatocellular carcinoma (HCC), researchers sa...

Drugs and Medications [46 Associated Drugs and Medications listed on BioPortfolio]

Dawn [Procter & Gamble Manufacturing Company]

Dawn Ultra Concentrated Extra Action AB

Dawn [Procter & Gamble Manufacturing Company]

Dawn Ultra Concentrated plus Power Scrubber Orange AB

Dawn [Procter & Gamble Manufacturing Company]

Dawn Ultra Concentrated plus Power Scrubber Apple Blossom AB

Dawn [Procter & Gamble Manufacturing Company]

Dawn Ultra Concentrated Apple Blossom AB

Dawn [Procter & Gamble Manufacturing Company]

Dawn Ultra Concentrated Orange AB

PubMed Articles [2593 Associated PubMed Articles listed on BioPortfolio]

Diagnosis of viral hepatitis.

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and HIV-HBV and HCV coinfection are major causes of chronic liver disease worldwide. Testing and diagnosis is the gateway for acc...

Immune Response And Anamnestic Immune Response In Children After A 3-Dose Primary Hepatitis B Vaccination.

Diseases caused by Hepatitis B virus (HBV) have a worldwide distribution. Pakistan adopted the recommendations of World Health Organization (WHO) for routine universal infant vaccination against hepat...

Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.

In 70 chronic hepatitis B patients with hepatitis B surface antigen seroclearance during nucleos(t)ide analogue therapy, response was sustained in all 54 patients who discontinued treatment. Clinicall...

Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.

It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to c...

Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients.

The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a indivi...

Clinical Trials [3846 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study

An important reason for the costs of hemodialysis treatment in China are expensive is the hemodialysis machine and related products mainly rely on imports. Hemodialysis machine is the basi...

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. ...

Immune Response to Hepatitis C Virus

The purpose of the study is to investigate the immune response to hepatitis C virus to determine why some people clear the virus and others develop chronic infection. Changes in immune re...

Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C

Pegylation of interferon prolongs the medication half-life which has resulted in Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C. We current this cl...

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibod...

Companies [935 Associated Companies listed on BioPortfolio]

The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C

Hepatitis B Foundation

The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through resear...

World Hepatitis Alliance

The following people have provided quotes expressing their support to the World Hepatitis Alliance campaign for a WHO resolution on viral hepatitis. For further information please contact worldhep...

National Domestic Violence Hotline

The National Domestic Violence Hotline was established in 1996 as a component of the Violence Against Women Act (VAWA) passed by Congress and is supported by funding from the U.S. Department of Health...

iQur Ltd

iQur® is a specialty pharmaceutical company at the forefront of international breakthroughs in the detection, treatment and monitoring of Hepatitis C and other liver diseases.iQur exists to provide c...

More Information about "The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C" on BioPortfolio

We have published hundreds of The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C news stories on BioPortfolio along with dozens of The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C Clinical Trials and PubMed Articles about The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C Companies in our database. You can also find out about relevant The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record